Transglutaminase 2 expression induced by lipopolysaccharide stimulation together with NO synthase induction in cultured astrocytes

Neurochemistry International

Volumn 57, Issue 7, 2010, Pages 812-818

  Takano, K ^a   Shiraiwa, K ^a   Moriyama, M ^a   Nakamura, Y ^a  

^a Osaka Prefecture University   (Japan)

Author keywords

Astrocyte; Cystamine; Ethyl pyruvate; INOS; NO production; Nuclear factor B; Transglutaminase 2

Indexed keywords

CYSTAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PYRUVIC ACID;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE; CELL CULTURE; DEGENERATIVE DISEASE; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INDUCTION; HIPPOCAMPUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ASTROCYTES; CELLS, CULTURED; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GTP-BINDING PROTEINS; LIPOPOLYSACCHARIDES; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PREGNANCY; RATS; RATS, WISTAR; TRANSGLUTAMINASES;

RATTUS;

EID: 77958091268     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.08.019     Document Type: Article

References (55)

1. Aeschlimann D., Thomazy V. Protein crosslinking in assembly and remodeling of extracellular matrices: the role of transglutaminase. Connect. Tissue Res. 2000, 41:1-27.
2. Benarroch E.E. Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. Mayo Clin. Proc. 2005, 80:1326-1338.
3. Caccamo D., Campisi A., Currò M., Aguennouz M., Li Volti G., Avola R., Ientile R. Nuclear factor-κB activation is associated with glutamate-evoked tissue transglutaminase up-regulation in primary astrocyte cultures. J. Neurosci. Res. 2005, 82(6):858-865.
4. Caccamo D., Campisi A., Currò M., Bramanti V., Tringali M., Li Volti G., Vanella A., Ientile R. Antioxidant treatment inhibited glutamate-evoked NF-κB activation in primary astroglial cell cultures. NeuroToxicology 2005, 26(5):915-921.
5. Campici A., Caccamo D., Li Volti G., Currò M., Parisi G., Avola R., Vanella A., Ientile R. Glutamate-evoked redox state alterations are involved in tissue transglutaminase upregulation in primary astrocyte cultures. FEBS Lett. 2004, 578(1-2):80-84.
6. Campici A., Caccamo D., Raciti G., Cannavò G., Macaione V., Currò M., Macaione S., Vanella A., Ientile R. Glutamate-induced increases in transglutaminase activity in primary cultures of astroglial cells. Brain Res. 2003, 978(1-2):24-30.
7. Campisi A., Renis M., Russo A., Sorrenti V., Di Giacomo C., Castorina C., Vanella A. Transglutaminase activity in primary and subcultured rat astroglial cells. Neurochem. Res. 1992, 17:1201-1205.
8. Catani M.V., Bernassola F., Rossi A., Melino G. Inhibition of clotting factor XIII activity by nitric oxide. Biochem. Biophys. Res. Commun. 1998, 249:275-278.
9. Chadi G., Maximino J.R., Oliveira G.P. The importance of molecular histology to study glial influence on neurodegenerative disorders. Focus on recent developed single cell laser microdissection. J. Mol. Histol. 2009, 40:241-250.
10. Citron B.A., SantaCruz K.S., Davies P.J.A., Festoff B.W. Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease. J. Biol. Chem. 2001, 276:3295-3301.
11. Faure E., Thomas L., Xu H., Medvedev A., Equils O., Arditi M. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J. Immunol. 2001, 166:2018-2024.
12. Fesus L., Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem. Sci. 2002, 27(10):534-539.
13. Folk J.E. Transglutaminases. Ann. Rev. Biochem. 1980, 49:517-531.
14. Folk J.E., Chung S.-I. Transglutaminases. Methods Enzymol. 1985, 113:358-375.
15. Frantz S., Kobzik L., Kim Y.D., Fukazawa R., Medzhitov R., Lee R.T., Kelly R.A. Toll-like receptor 4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J. Clin. Invest. 1999, 104:271-280.
16. Griffin M., Casadio R., Bergamini C.M. Transglutaminase: nature's biological glues. Biochem. J. 2002, 368(2):377-396.
17. Hori O., Ichinoda F., Yamaguchi A., Tamatani T., Taniguchi M., Koyama Y., Katayama T., Tohyama M., Stern D.M., Ozawa K., Kitao Y., Ogawa S. Role of Herp in the endoplasmic reticulum stress response. Genes Cells 2004, 9:457-469.
18. Ientile R., Caccamo D., Griffin M. Tissue transglutaminase and the stress response. Amino Acids 2007, 33(2):385-394.
19. Ientile R., Campici A., Raciti G., Caccamo D., Currò M., Cannavò G., Li Volti G., Macaione S., Vanella A. Cystamine inhibits transglutaminase and caspase-3 cleavage in glutamate-exposed astroglial cells. J. Neurosci. Res. 2003, 74:52-59.
20. Jeitner T.M., Muma N.A., Battaile K.P., Cooper A.J.L. Transglutaminase activation in neurodegenerative diseases. Future Neurol. 2009, 4:449-467.
21. Johnson G.V.W., Cox T.M., Lockhart J.P., Zinnerman M.D., Miller M.L., Powers R.E. Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res. 1997, 751:323-329.
22. Junn E., Ronchetti R.D., Quezado M.M., Kim S.Y., Mouradian M.M. Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2047-2052.
23. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., Mitchell D., Steinman L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 2002, 8(2):143-149.
24. Kim J.-B., Yu Y.-M., Kim S.-W., Lee J.-K. Anti-inflammatory mechanism is involved in ethyl pyruvate-mediated efficacious neuroprotection in the postischemic brain. Brain Res. 2005, 1060:188-192.
25. Kim S.-Y., Grant P., Lee J.-H., Pant H.C., Steinert P.M. Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. J. Biol. Chem. 1999, 274:30715-30721.
26. Kim S.-Y., Jeitner T.M., Steinert P.M. Transglutaminases in disease. Neurochem. Int. 2002, 40:85-103.
27. Lai T.S., Hausladen A., Slaughter T.F., Eu J.P., Stamler J.S., Greenberg C.S. Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase. Biochemistry 2001, 40:4904-4910.
28. Lee J., Kim Y.-S., Choi D.-H., Bang M.S., Han T.Y., Joh T.H., Kim S.-Y. Transglutaminase 2 induces nuclear factor-κB activation via a novel pathway in BV-2 microglia. J. Biol. Chem. 2004, 279:53725-53735.
29. Lee J.Y., Lowell C.A., Lemay D.G., Youn H.S., Rhee S.H., Sohn K.H., Jang B., Ye J., Chung J.H., Hwang D.H. The regulation of the expression of inducible nitric oxide synthase by Src-family tyrosine kinases mediated through MyD88-independent signaling pathways of Toll-like receptor 4. Biochem. Pharmacol. 2005, 70:1231-1240.
30. Lee S.Y., Son D.J., Lee Y.K., Lee J.W., Lee H.J., Yun Y.W., Ha T.Y., Hong J.T. Inhibitory effect of sesaminol glucosides on lipopolysaccharide-induced NF-κB activation and target gene expression in cultured rat astrocytes. Neurosci. Res. 2006, 56:204-212.
31. Lee Z.-W., Kwon S.-M., Kim S.-W., Yi S.-J., Kim Y.-M., Ha K.-S. Activation of in situ tissue transglutaminase by intracellular reactive oxygen species. Biochem. Biophys. Res. Commun. 2003, 305:633-640.
32. Lesort M., Chun W., Johnson G.V.W., Ferrante R.J. Tissue transglutaminase is increased in Huntington's disease brain. J. Neurchem. 1999, 73:2018-2027.
33. Lesort M., Lee M., Tucholski J., Johnson G.V.W. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J. Biol. Chem. 2003, 278(6):3825-3830.
34. Lesort M., Tucholski J., Miller M.L., Johnson G.V.W. Tissue transglutaminase: a possible role in neurodegenerative diseases. Prog. Neurobiol. 2000, 61:439-463.
35. Martin L., Pingle S.C., Hallam D.M., Rybak L.P., Ramkumar V. Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J. Pharmacol. Exp. Ther. 2006, 316(1):71-78.
36. Monsonego A., Shani Y., Friedmann I., Paas Y., Eizenberg O., Schwartz M. Expression of GTP-dependent and GTP-independent tissue-type transglutaminase in cytokine-treated rat brain astrocytes. J. Biol. Chem. 1997, 272:3724-3732.
37. Murakami K., Nakamura Y., Yoneda Y. Potentiation by ATP of lipopolysaccharide-stimulated nitric oxide production in cultured astrocytes. Neuroscience 2003, 117:37-42.
38. Nomura Y. NF-kappaB activation and IkappaB alpha dynamism involved in iNOS and chemokine induction in astroglial cells. Life Sci. 2001, 68:1695-1701.
39. Palsson-McDermott E.M., O'Neill L.A. Signal transduction by the lipopolysaccharide receptor, toll-like receptor-4. Immunology 2004, 113:153-162.
40. Park K.C., Chung K.C., Kim Y.-S., Lee J., Joh T.H., Kim S.-Y. Transglutaminase 2 induces nitric oxide synthesis in BV-2 microglia. Biochem. Biophys. Res. Commun. 2004, 323:1055-1062.
41. Pawate S., Shen Q., Fan F., Bhat N.R. Redox regulation of glial inflammatory response to lipopolysaccharide and interferon γ. J. Neurosci. Res. 2004, 77:540-551.
42. Qin L., Liu Y., Wang T., Wei S.-J., Block M.L., Wilson B., Liu B., Hong J.-S. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem. 2004, 279(2):1415-1421.
43. Raha S., Robinson B.H. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. Sci. 2000, 25:502-508.
44. Rossi A., Catani M.V., Candi E., Bernassola F., Puddu P., Melino G. Nitric oxide inhibits cornified envelope formation in human keratinocytes by inactivating transglutaminases and activating protein 1. J. Invest. Dermatol. 2000, 115:731-739.
45. Schipper H.M., Gupta A., Szarek W.A. Suppression of glial HO-1 activity as a potential neurotherapeutic intervention in AD. Curr. Alzheimer Res. 2009, 6(5):424-430.
46. Si Q.S., Nakamura Y., Kataoka K. Hypothermic suppression of microglial activation in culture: inhibition of cell proliferation and production of nitric oxide and superoxide. Neuroscience 1997, 81:223-229.
47. Takano K., Nakamura Y., Yoneda Y. Microglial cell death induced by a low concentration of polyamines. Neuroscience 2003, 120:961-967.
48. Takano K., Ogura M., Yoneda Y., Nakamura Y. Oxidative metabolites are involved in polyamine-induced microglial cell death. Neuroscience 2005, 134:1123-1131.
49. Tolentino P.J., Waghray A., Wang K.K.W., Hayes R.L. Increased expression of tissue-type transglutaminase following middle cerebral artery occlusion in rats. J. Neurochem. 2004, 89:1301-1307.
50. Tsacopoulos M., Poitry-Yamate C.L., Poitry S., Perrottet P., Veuthey A.L. The nutritive function of glia is regulated by signals released by neurons. Glia 1997, 21:84-91.
51. Varvel N.H., Bhaskar K., Kounnas M.Z., Wagner S.L., Yang Y., Lamb B.T., Herrup K. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J. Clin. Invest. 2009, 119(12):3692-3702.
52. 2 in microglia. J. Neurochem. 2004, 88:939-947.
53. Wilhelmus M.M.M., Dam A.-M., Drukarch B. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases. Eur. J. Pharmacol. 2008, 585:464-472.
54. Yamada T., Yoshiyama Y., Kawaguchi N., Ichinose A., Iwaki T., Hirose S., Jefferies W.A. Possible roles of transglutaminases in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 1998, 9:103-110.
55. Zhang J., Lesort M., Guttmann R.P., Johnson G.V.W. Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J. Biol. Chem. 1998, 273(4):2288-2295.